Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Rev Esp Enferm Dig ; 108(6): 364-5, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-27324518

RESUMEN

Granular cell tumors are uncommon in the gastrointestinal tract. They are often found incidentally during colonoscopic examination performed for other reasons as they are frequently asymptomatic and benign. They usually present as submucosal lesions that can be endoscopically resected. The final diagnosis depends on histopathological findings. We present the case of a 47-year-old man that underwent an endoscopic resection of several polyps at the time of colonoscopy with nonspecific complaints and family history of colorectal carcinoma.


Asunto(s)
Neoplasias del Ciego/patología , Tumor de Células Granulares/patología , Neoplasias del Ciego/cirugía , Diagnóstico Diferencial , Tumor de Células Granulares/cirugía , Humanos , Masculino , Persona de Mediana Edad , Proteínas S100/análisis , Proteínas S100/metabolismo
2.
Haematologica ; 95(8): 1342-9, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20418245

RESUMEN

BACKGROUND: Plasmablastic lymphoma has recently come to be considered a distinct entity among mature B cell neoplasms, although the limits with diffuse large B-cell lymphoma (DLBCL) need to be more accurately defined. DESIGN AND METHODS: Here we show the results of an immunohistochemical study of 35 cases of plasmablastic lymphoma compared with a set of 111 conventional DLBCLs. RESULTS: Our results demonstrate that the use of a limited combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables the identification of a plasmablastic immunophenotype highly characteristic of plasmablastic lymphoma cases and associated with an aggressive clinical behavior. Additionally, the study shows that the acquisition of a partial plasmablastic phenotype (PRDM1/BLIMP1 expression) in DLBCL is associated with shorter survival in R-CHOP-treated patients. CONCLUSIONS: The use of a restricted combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables a more accurate definition of terminal differentiation for large B-cell lymphoma.


Asunto(s)
Linfoma de Células B/metabolismo , Linfoma de Células B Grandes Difuso/metabolismo , Células Plasmáticas/química , Adulto , Anciano , Anciano de 80 o más Años , Antígenos CD20/metabolismo , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Diferenciación Celular , Femenino , Humanos , Inmunohistoquímica , Inmunofenotipificación , Linfoma de Células B/tratamiento farmacológico , Linfoma de Células B/patología , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/patología , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Factor de Transcripción PAX5/metabolismo , Células Plasmáticas/efectos de los fármacos , Células Plasmáticas/patología , Factor 1 de Unión al Dominio 1 de Regulación Positiva , Proteínas Represoras/metabolismo , Análisis de Supervivencia , Resultado del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA